Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

It's a decision no woman wants to have to make, but new research shows that young breast cancer patients with high-ris ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...

RISK-REDUCING surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved ...

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

Leerink Partnrs lowered their Q1 2025 EPS estimates for Myriad Genetics in a research report issued on Monday, December 9th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ...

Me, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In ...

Some early breast cancer patients can safely avoid certain surgeries. That's according to two studies published Thursday that ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Women with a type of low-risk cancer might not have to rush aggressive treatment, doctors say.